Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab + nivolumab with multisite hypofractionated radiotherapy after chemo-pembrolizumab failure in metastatic NSCLC
NL-OMON49121Phase 2Completed
- Sponsor
- Vrije University Medical Center
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in non-small cell lung cancer (NSCLC), sponsored by Vrije University Medical Center. Primary endpoints: Safety, Objective response rate and 1 more. Started Sep 2020; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49121.